Authors
Latest:
PI3K Inhibitors, Oral SERDs, Combination Therapies, and the Shifting Treatment LandscapePanelists discuss ongoing clinical trials and how the treatment landscape for HR positive (HR+)/ HER2 negative (HER2-) breast cancer is evolving with novel targeted therapies and combination strategies, with Dr Isaacs highlighting the most exciting aspects of these trials and their potential impact on the future of precision medicine in this patient population.
Latest:
Case 2: Patient With High-Risk RRMM Relapsing After BCMA CAR T-Cell TherapyPanelists discuss how patients relapsing shortly after BCMA CAR T-cell therapy should receive GPRC5D-targeted bispecifics rather than repeat BCMA therapies, given the evidence that prior BCMA exposure reduces efficacy of subsequent BCMA-directed treatments.
Latest:
Cardiovascular Considerations in Breast Cancer Treatment and SurvivorshipUp-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.
Latest:
Practice Pearls for Optimizing the Management of Advanced RCCExperts Ulka N. Vaishampayan, MBBS, and Moshe Ornstein, MD, look toward the future treatment paradigm of both clear cell and non–clear cell renal cell carcinoma.
Latest:
Guidelines for Opioid Use in Cancer Management are Needed, Expert SaysAlthough opioid use guidelines from the Centers for Disease Control exclude patients with cancer, drug screenings are required that could further contribute to racial disparities.
Latest:
Should Those with Non-Hodgkin Lymphoma Receive CAR T or Bispecifics?Although data for bispecific antibodies are maturing, CAR T-cell therapy has longer-term data that show prolonged and durable efficacy in LBCL.
Latest:
Clinical Pearls about the Referral Process of Bispecifics and CAR-T in RRMMThe discussion shares key takeaways and practical insights for optimizing the referral and treatment process for CAR T-cell and bispecific therapies.
Latest:
Artificial Intelligence May Expedite Prognoses in Cancer CareIn considering patients’ busy lives, AI may help reduce the number of visits required to fully stage and grade cancers.
Latest:
Synchronous Well-Differentiated Papillary Mesothelioma and Endometrioid Adenocarcinoma Arising From EndometriosisLearn more about a 56-year-old woman diagnosed with well-differentiated papillary mesothelioma, and how she was diagnosed and properly treated.
Latest:
The Future of DLBCL: Innovations in Therapy and Patient CarePanelists discuss how the treatment landscape for diffuse large B-cell lymphoma (DLBCL) is poised for transformation as novel chimeric antigen receptor T-cell approaches integrate with existing therapies, enhancing efficacy and durability. Insights from Tandem 2025 highlight advancements in cellular therapy, including combinatorial strategies and next-generation chimeric antigen receptor T-cell designs, driving optimism for improved patient outcomes.
Latest:
Telehealth and Treatment Selection: Highlights From an Expert Panel on Multiple MyelomaA Satellite Sessions program panel at the University of Texas MD Anderson Cancer Center discusses topics in multiple myeloma including the selection of triplet vs quadruplet treatment regimens and optimizing outcomes in the maintenance setting.
Latest:
Key Takeaways and Future Directions in Later Relapsed/Refractory MMPanelists discuss how talquetamab’s unique targeting mechanism offers significant advantages for patients with prior T-cell therapy exposure, whereas future research should focus on combination strategies and understanding primary resistance mechanisms.
Latest:
GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast CancerPatients with breast cancer experience significant weight loss after using GLP-1 receptor agonists, highlighting potential benefits for obesity management in this population.
Latest:
Empowering Ovarian Cancer Patients: How to Educate and Support Those Starting ADC TherapyCounseling Patients on ADC Side Effects Patient education is a cornerstone of successful ADC treatment. When introducing ADCs, providers focus on transparency—discussing the most common side effects upfront and reinforcing that many are reversible with dose holds or modifications. Eye toxicities and lung-related side effects like pneumonitis often cause anxiety. Clear communication and reassurance that these can be managed effectively help build trust. Educational materials and follow-up calls ensure patients feel supported and informed. Ultimately, the goal is to empower patients to report symptoms early and remain engaged in their care. ADC therapy offers significant clinical benefit, and with proactive management, patients can achieve extended survival and maintain their quality of life throughout treatment.
Latest:
Predictors of Poor Adherence to Follow-up Care in Survivors of Childhood CancerRahiya Rehman, MD, and co-investigators, research the importance of poor follow-up and care for survivors of childhood cancer.
Latest:
Multiprong Leukemia Efforts Boost the Atlantic Health System Heme/Onc ProgramAn upcoming program from Atlantic Health System physicians apprising key data from the American Society of Hematology Annual Meeting & Exposition brings in faculty from top programs to share research updates.
Latest:
Treatment of Multiple Myeloma: Q&A Session With Yale Cancer Center and SatellitesA Q&A session with the expert panel.
Latest:
Complex ES-SCLC Case: Tarlatamab Management Through Toxicity to Clinical BenefitPanelists discuss how effective management of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome in complex extensive-stage small cell lung cancer (ES-SCLC) cases treated with tarlatamab enables patients to continue therapy and achieve meaningful clinical benefit despite early toxicities.
Latest:
Which Treatment for Which Patient: Rectal Cancer Management After PROSPECT TrialDetermining treatment options for patients with locally advanced rectal cancer after the PROSPECT trial data readout adds an important level to the decision-making process.
Latest:
A Multidisciplinary Approach to Treating Resectable NSCLCSurgeons, radiation oncologists, and medical oncologists gathered to discuss treatment options and approaches for NSCLC.
Latest:
Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative TrialsThe June Hot Topics focuses on the challenges venetoclax regimens have faced in multiple myeloma trials.
Latest:
Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer CenterExperts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.
Latest:
Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBCProspective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.
Latest:
Advice for Patients, Nurse Practitioners, and Community Oncologists on Teclistamab Therapy in Multiple MyelomaThe panel shares closing advice for patients with multiple myeloma receiving teclistamab, and community providers and nurse practitioners administering teclistamab to patients.
Latest:
Optimizing Surgery With New AI Technologies in Breast and Ovarian Cancer“Frozen section is destructive. It ruins the tissue, it consumes the tissue, and it affects downstream molecular analysis,” according to Farzad Fereidouni, PhD.
